Specify a stock or a cryptocurrency in the search bar to get a summary
Oncolytics Biotech Inc
ONCYOncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. Address: 322 11th Avenue SW, Calgary, AB, Canada, T2R 0C5
Analytics
WallStreet Target Price
9.52 CADP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ONCY
Dividend Analytics ONCY
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ONCY
Stock Valuation ONCY
Financials ONCY
Results | 2019 | Dynamics |